no large-scale controlled trials Lack of FDA approval process No sponsor has pursued formal approval Quality concerns Peptide impurities and characterization challenges in unregulated manufacturing The economic reality: Unpatentable peptides cant justify the $50100M+ investment required for Phase 3 clinical trials, which is why BPC-157 has peer-reviewed preclinical data but no completed human trials
For some, it is weight loss, while others are using peptides to help them with muscle mass
SIM1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus
Tuyt i khng t truyn trng da ti nh Hin nay, trong lnh vc lm p c rt nhiu a im thc hin vi cht lng, gi c rt khc nhau
Because the peptide has not been extensively studied in humans, researchers do not yet fully understand its potential side effects, drug interactions, or long-term health implications